Medtronic Quarterly Income Statement
NYSE: MDTHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Medtronic revenue and earnings
In the quarter ended Jul 31, 2026, Medtronic generated $9.76 billion in revenue, up 13.7% from the same quarter a year earlier. Net income was $1.47 billion (+41.3% year over year), for a net margin of 15.1% versus a median of 12.7% in the prior 5 quarters. Gross margin was 65.0% (flat year over year) and operating margin 18.1%.
Diluted earnings per share came in at $1.14, up from $0.81.
Summary generated from market data by MetaCap's automated system. Methodology
Medtronic income statement (quarterly)
| Quarter (USD) | Q1 20272026-07-31 | Q4 20262026-04-24 | Q3 20262026-01-23 | Q2 20262025-10-24 | Q1 20262025-07-25 | Q4 20252025-04-25 | Q3 20252025-01-24 | Q2 20252024-10-25 | Q1 20252024-07-26 | Q4 20242024-04-26 | Q3 20242024-01-26 | Q2 20242023-10-27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.76B | 9.81B | 9.02B | 8.96B | 8.58B | 8.93B | 8.29B | 8.40B | 7.92B | 8.59B | 8.09B | 7.98B |
| Revenue growth (YoY) | +13.73% | +9.86% | +8.74% | +6.64% | +8.38% | +3.94% | +2.51% | +5.25% | +2.77% | +0.51% | +4.68% | +5.26% |
| Cost of Revenue | 3.42B | 3.40B | 3.26B | 3.06B | 3.00B | 3.15B | 2.78B | 2.95B | 2.76B | 3.04B | 2.78B | 2.76B |
| Gross Profit | 6.34B | 6.41B | 5.76B | 5.90B | 5.58B | 5.78B | 5.51B | 5.46B | 5.15B | 5.54B | 5.31B | 5.22B |
| Operating Expenses | 4.58B | 4.54B | 4.29B | 4.21B | 4.13B | 4.34B | 3.87B | 3.86B | 3.88B | 4.49B | 3.82B | 3.88B |
| Research & Development | 771.00M | 671.00M | 722.00M | 754.00M | 726.00M | 684.00M | 675.00M | 697.00M | 676.00M | 675.00M | 695.00M | 698.00M |
| Selling, General & Admin | 3.20B | 3.06B | 2.96B | 2.96B | 2.81B | 2.72B | 2.72B | 2.76B | 2.65B | 2.77B | 2.67B | 2.69B |
| Operating Income | 1.76B | 1.87B | 1.46B | 1.69B | 1.45B | 1.44B | 1.65B | 1.59B | 1.28B | 1.05B | 1.48B | 1.34B |
| Interest Expense | 186.00M | 176.00M | 181.00M | 181.00M | 176.00M | 174.00M | 179.00M | 209.00M | 167.00M | 202.00M | 188.00M | 180.00M |
| Other Income (Expense) | 190.00M | 137.00M | 121.00M | 92.00M | 33.00M | -1.00M | 72.00M | 173.00M | 157.00M | 5.00M | 177.00M | 154.00M |
| Pretax Income | 1.77B | 1.83B | 1.40B | 1.60B | 1.30B | 1.26B | 1.54B | 1.56B | 1.27B | 855.00M | 1.47B | 1.31B |
| Income Tax | 289.00M | 575.00M | 254.00M | 215.00M | 255.00M | 199.00M | 237.00M | 281.00M | 220.00M | 197.00M | 135.00M | 402.00M |
| Net Income | 1.47B | 1.24B | 1.14B | 1.37B | 1.04B | 1.06B | 1.29B | 1.27B | 1.04B | 654.00M | 1.32B | 909.00M |
| Net Income growth (YoY) | +41.35% | +17.80% | -11.67% | +8.19% | -0.19% | +61.47% | -2.12% | +39.71% | +31.73% | -44.53% | +8.18% | +112.88% |
| EPS (Basic) | 1.15 | 0.98 | 0.89 | 1.07 | 0.81 | 0.82 | 1.01 | 0.99 | 0.81 | 0.51 | 0.99 | 0.68 |
| EPS (Diluted) | 1.14 | 0.96 | 0.89 | 1.07 | 0.81 | 0.81 | 1.01 | 0.99 | 0.80 | 0.50 | 0.99 | 0.68 |
| Shares Outstanding (Basic) | 1.28B | — | 1.28B | 1.28B | 1.28B | — | 1.28B | 1.28B | 1.29B | — | 1.33B | 1.33B |
| Shares Outstanding (Diluted) | 1.29B | — | 1.29B | 1.29B | 1.29B | — | 1.29B | 1.29B | 1.30B | — | 1.33B | 1.33B |
| EBITDA | 2.49B | 2.59B | 2.21B | 2.43B | 2.19B | 2.28B | 2.33B | 2.27B | 1.94B | 1.71B | 2.13B | 2.01B |
| Gross Margin | 64.99% | 65.35% | 63.83% | 65.84% | 65.02% | 64.75% | 66.49% | 64.94% | 65.12% | 64.56% | 65.61% | 65.42% |
| Operating Margin | 18.08% | 19.10% | 16.24% | 18.81% | 16.85% | 16.09% | 19.85% | 18.98% | 16.15% | 12.26% | 18.33% | 16.78% |
| Net Margin | 15.07% | 12.68% | 12.68% | 15.33% | 12.12% | 11.83% | 15.61% | 15.11% | 13.16% | 7.61% | 16.34% | 11.39% |
This table shows 12 quarterly periods of Medtronic's income statement, from Q1 2027 back to Q2 2024, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow MDT's reporting calendar. What is a income statement?